Literature DB >> 27236331

Transcription Factor NF-κB: An Update on Intervention Strategies.

Arvind Panday1,2, Maria Eugenia Inda3, Prathyusha Bagam4, Malaya K Sahoo5, Diana Osorio1, Sanjay Batra6,7.   

Abstract

The nuclear factor (NF)-κB family of transcription factors are ubiquitous and pleiotropic molecules that regulate the expression of more than 150 genes involved in a broad range of processes including inflammation, immunity, cell proliferation, differentiation, and survival. The chronic activation or dysregulation of NF-κB signaling is the central cause of pathogenesis in many disease conditions and, therefore, NF-κB is a major focus of therapeutic intervention. Because of this, understanding the relationship between NF-κB and the induction of various downstream signaling molecules is imperative. In this review, we provide an updated synopsis of the role of NF-κB in DNA repair and in various ailments including cardiovascular diseases, HIV infection, asthma, herpes simplex virus infection, chronic obstructive pulmonary disease, and cancer. Furthermore, we also discuss the specific targets for selective inhibitors and future therapeutic strategies.

Entities:  

Keywords:  Asthma; COPD; Cancer; DNA damage; HIV; HSV; NF-κB

Mesh:

Substances:

Year:  2016        PMID: 27236331     DOI: 10.1007/s00005-016-0405-y

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  31 in total

Review 1.  Genomics, Biology, and Human Illness: Advances in the Monogenic Autoinflammatory Diseases.

Authors:  Hirotsugu Oda; Daniel L Kastner
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

Review 2.  The Emerging Roles of STING in Bacterial Infections.

Authors:  Fabio V Marinho; Sulayman Benmerzoug; Sergio C Oliveira; Bernhard Ryffel; V F J Quesniaux
Journal:  Trends Microbiol       Date:  2017-06-15       Impact factor: 17.079

3.  Dual Functional MicroRNA-186-5p Targets both FGF2 and RelA to Suppress Tumorigenesis of Glioblastoma Multiforme.

Authors:  Fachen Wang; Hui Jiang; Shanjun Wang; Bing Chen
Journal:  Cell Mol Neurobiol       Date:  2017-02-17       Impact factor: 5.046

4.  A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

Authors:  Xin-Shuai Wang; De-Jiu Kong; Tzu-Yin Lin; Xiao-Cen Li; Yoshihiro Izumiya; Xue-Zhen Ding; Li Zhang; Xiao-Chen Hu; Jun-Qiang Yang; She-Gan Gao; Kit S Lam; Yuan-Pei Li
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

5.  Urban particulate matter triggers lung inflammation via the ROS-MAPK-NF-κB signaling pathway.

Authors:  Jian Wang; Jianan Huang; Linlin Wang; Cuicui Chen; Dong Yang; Meiling Jin; Chunxue Bai; Yuanlin Song
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 6.  The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy.

Authors:  Yaojie Fu; Shanshan Liu; Shanghelin Yin; Weihong Niu; Wei Xiong; Ming Tan; Guiyuan Li; Ming Zhou
Journal:  Oncotarget       Date:  2017-05-25

7.  MCL Plays an Anti-Inflammatory Role in Mycobacterium tuberculosis-Induced Immune Response by Inhibiting NF-κB and NLRP3 Inflammasome Activation.

Authors:  Qingwen Zhang; Xinru Jiang; Weigang He; Kailin Wei; Jinxia Sun; Xiangyang Qin; Yuejuan Zheng; Xin Jiang
Journal:  Mediators Inflamm       Date:  2017-05-31       Impact factor: 4.711

8.  HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.

Authors:  Lanlan Tang; Wenwen Chai; Fanghua Ye; Yan Yu; Lizhi Cao; Minghua Yang; Min Xie; Liangchun Yang
Journal:  Oncotarget       Date:  2017-04-18

Review 9.  NF-κB Signalling in Glioblastoma.

Authors:  Vincent Soubannier; Stefano Stifani
Journal:  Biomedicines       Date:  2017-06-09

Review 10.  Transcriptomics, NF-κB Pathway, and Their Potential Spaceflight-Related Health Consequences.

Authors:  Ye Zhang; Maria Moreno-Villanueva; Stephanie Krieger; Govindarajan T Ramesh; Srujana Neelam; Honglu Wu
Journal:  Int J Mol Sci       Date:  2017-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.